Regulatory approval

Published by the Health Canada. Approved

GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.

This is written in the approval document.

Citation

Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083190.PDF. Revised January 2026. Accessed April 2026.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HC (1) PDGFRA rearrangements Myelodysplastic Syndromes Imatinib
HC (1) PDGFRB rearrangements Myelodysplastic Syndromes Imatinib
HC (1) PDGFRA rearrangements Myeloproliferative Neoplasm Imatinib
HC (1) PDGFRB rearrangements Myeloproliferative Neoplasm Imatinib

Contributions

Date Contributor Description
2024-10-30 Van Allen lab Initial access of FDA approvals